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ABSTRACT 
Purpose: A first analysis of simultaneous 68Ga-PSMA-11 PET/MRI showed some improvement in the 
detection of recurrent disease at low serum prostate specific antigen (PSA) values below 0.5 ng/ml 
compared to the already high detection rate of 68Ga-PSMA-11 PET/CT. We therefore focused on all 
patients with biochemical recurrence (BR) and PSA values ≤ 0.5 ng/ml to assess the detection rate for 
68Ga-PSMA-11 PET/MRI. 
Methods: We retrospectively analyzed a cohort of 66 consecutive patients who underwent a 68Ga-
PSMA-11 PET/MRI for BR with a PSA value ≤ 0.5 ng/ml at our institution. Median PSA level was 0.23 
ng/ml (range: 0.03 – 0.5 ng/ml). Detection of PSMA-positive lesions within the prostate fossa, local and 
distant lymph nodes, bones or visceral organs was recorded. In addition, all scans with 68Ga-PSMA-11 
PET/MRI positive lesions were retrospectively assessed to analyze if lesions were detected inside or 
outside of a standard salvage radiotherapy volume. 
Results: Overall, in 36 of 66 patients (54.5%) PSMA-positive lesions were detected; in 26 of 40 (65%) 
patients with a PSA between 0.2 - 0.5 ng/ml and in 10 of 26 (38.5%) patients with a PSA < 0.2 ng/ml. 
Even at those low PSA values, only 8 of 66 (12.1%) patients had exclusive local recurrence. In 23 
patients lymph nodes and in 5 patients bone metastases were detected on 68Ga-PSMA-11 PET/MRI. 
In 26 of 66 patients (39.4%) PSMA-positive lesions were located outside a standard salvage 
radiotherapy volume. 
Conclusion: Our data confirm that 68Ga-PSMA-11 PET/MRI has a high detection rate for recurrent 
prostate cancer, even at low PSA levels ≤ 0.5 ng/ml. In addition, we show that 68Ga-PSMA-11 PET/MRI 
detected PSMA-positive lesions outside a standard salvage radiotherapy volume in 39.4% of all 
patients. 
 
Key words (MESH-keywords): Prostate Cancer, Prostate-Specific Antigen, 68Ga-PSMA-11, Positron 
Emission Tomography, PSMA Antigen 
  
 3 
INTRODUCTION 
Salvage radiotherapy (sRT) to the prostatic bed is still the only localized treatment option for patients 
with biochemical recurrence (BR) following radical prostatectomy. Early sRT, in patients treated before 
PSA levels rise to > 0.5 ng/ml, will achieve undetectable PSA levels in more than 60% of the patients, 
while providing a 80% change of 5-year progression-free survival (1). Yet, for those 30% of patients 
without any effect on PSA levels due to extrapelvic localization of the recurrence, sRT to the prostatic 
bed is of limited value (2). 
Detection rates of choline positron emission tomography / computerized tomography (PET/CT) 
range only between 5 - 24% in patients with BR and PSA levels < 1 ng/mL following radical 
prostatectomy (3). In contrast, a recent meta-analysis demonstrated a detection rate of 45% (95% 
confidence interval 39 - 52%) using the new 68Gallium labeled PET tracer targeting the prostate specific 
membrane antigen (PSMA) in patients with BR and PSA values of 0.2 – 0.49 ng/ml (4). PSMA-based 
targeted radiotherapy might therefore become a therapeutic option in patients with BR (5,6). However, 
data about the oncological outcome of PSMA-based targeted radiotherapy is still limited and ongoing 
clinical trials have to be completed before definitive conclusions regarding the effect of targeted salvage 
treatments can be drawn (7). The superior soft tissue contrast of PET/MRI might further improve the 
detection of pelvic lesions and indeed first preliminary results for 68Ga-PSMA-11 PET/MRI showed that 
especially in patients with very low PSA values, the detection rate was higher compared to the published 
results for PET/CT (8). However, this was based on a small patient number. Hence, robust results for 
the performance of PET/MRI in patients with very low PSA values are still missing. 
Furthermore, several studies showed that even at low PSA values, the detected lesions are not 
exclusively localized in the prostatic bed. In these cases an adaption of the target volume of sRT can 
be discussed. However, it has not been analyzed yet in how many cases 68Ga-PSMA-11 PET/MRI 
would possibly lead to a change or modification (e.g. with additional boost) of the target volume 
compared to a “classical” sRT to the prostate bed, as performed when macroscopic tumor is not 
detectable in patients with low PSA values. We aimed to analyze the detection rate of 68Ga-PSMA-11 
PET/MRI in patients with BR after radical prostatectomy and low PSA values ≤ 0.5 ng/ml. In addition, 
we aimed to retrospectively assess if lesions detected by 68Ga-PSMA-11 PET/MRI were detected 
outside a standard sRT volume.  
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MATERIALS AND METHODS 
Patients 
 We retrospectively analyzed all patients who received 68Ga-PSMA-11 PET/MRI 
for BR after radical prostatectomy at low PSA values ≤ 0.5 ng/ml scanned between April 2016 and 
December 2017 at our department. BR was confirmed in all patients by at least two consecutive PSA 
values. Patients with very low PSA values < 0.2 ng/ml were also included in the present analysis. The 
local ethics committee approved the study protocol (BASEC Nr. 2016-02230) and all patients had given 
a general written informed consent. Twenty patients from the previously published cohort investigating 
the detection rate of 68Ga-PSMA-11 PET/MRI for all PSA values were included in the present data set 
(8). Clinical parameters including PSA, primary tumor stage, Gleason score and surgical margin status 
were assessed. The detection rate of PSMA-positive lesions was analyzed overall and for 2 subgroups: 
very low PSA (0 - < 0.2 ng/ml) and low PSA (0.2 – 0.5 ng/ml). Further, the region of detection was 
assessed (prostatic fossa (including bed of seminal vesicles), pelvic, para-aortic, 
mediastinal/supraclavicular and axillary lymph nodes, bone lesions and visceral lesions). Detection of 
PSMA-positive lesions was separately analyzed for patients with prior or ongoing androgen-deprivation 
therapy (ADT). Patient with castration-resistant prostate cancer were excluded from the present 
analysis. In addition, the maximum standardized uptake value (SUVmax) and the lesion size were 
assessed. 
 
68Ga-PSMA-11 PET/MRI 
 All patients underwent a single injection of 68Ga-PSMA-11 (130 ± 16 MBq, range 
90-162 MBq). A clinical routine whole-body PET/MRI was performed 60 min after injection on a hybrid 
scanner (SIGNA PET/MR, GE Healthcare, Waukesha, WI, USA) used in previous studies at our 
department (8). In brief, the scanner comprises a 3-T MR system with TOF-PET detector ring installed 
between the body and gradient coils. A 3D dual-echo, spoiled gradient recalled echo sequence (LAVA-
FLEX) for AC and a PET emission scan was recorded in list mode. The whole-body protocol included 
six bed positions with 2 minutes acquisition time each. Specific sequences covering the pelvis, including 
a high resolution T1-weighted LAVA-FLEX sequence, T2-weighted fast recovery fast spin-echo 
sequence in two planes and diffusion weighted images (b values: 0, 300, 1000) were acquired with a 
15 min PET frame. Furosemide was injected intravenously 30 minutes prior to the 68Ga-PSMA-11 
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injection (0.13 mg/kg) to reduce halo artifacts (9). For attenuation correction an atlas-based MR-AC 
was used for the head, and for the remaining body air, lung, and soft tissue were segmented using the 
DIXON LAVA-FLEX sequences generating a fat-water based attenuation correction map. The protocol 
scan time was 30 minutes. 
 A dual board-certified radiologist and nuclear medicine physician (R1), 
incorporating both the MRI and PET information as well as all clinical information, analyzed all images. 
Furthermore, to investigate interreader variability 2 additional readouts were conducted. For the second 
read out the following clinical information was given: PSA at scan, stage and grade of primary tumor, 
surgical margins and Gleason score. Analog to our previous publication only lesions with high suspicion 
for recurrence were considered positive: focal 68Ga-PSMA-11 uptake in the soft tissue of the prostate 
bed, lymph nodes with an SUVmax ≥ 3 and/or pathologically increased size (≥ 5 mm for perirectal nodes, 
≥ 8 mm for iliac / retroperitoneal nodes, ≥ 1 cm for inguinal nodes), focal bone uptake with correlating 
bone marrow replacement or focal uptake with correlating soft tissue lesion (8). Most published series 
suggested values between SUVmax 2-3 as appropriate cut off values, especially for lymph nodes 
(10,11). To minimize false positive interpretation of slightly PSMA positive findings, a cut off of 3 was 
selected. 
 
Retrospective evaluation of the radiotherapy volume 
 All scans with 68Ga-PSMA-11 PET/MRI positive lesions were reviewed according 
to the EORTC and RTOG guidelines (12,13). Based on initial tumor stage, nodal status and surgical 
margins, as well as PSA value, the appropriate radiotherapy target (RT) volume was retrospectively 
defined based on both guidelines to define the target volume for salvage radiotherapy. If the 68Ga-
PSMA-11 PET/MRI positive lesions were located outside a standard salvage radiotherapy volume, a 
change in RT-volume was given. 
 
Statistical analysis 
 Statistical analysis was performed using IBM SPSS Statistics Version 25. 
GraphPad Prism version 7 (PraphPad Software, Inc. La Jolla, USA) was used to generate all images. 
Intraclass correlation coefficient was used to assess the interreader agreement. Ninety-five percent 
confidence intervals (CIs) are reported for kappa (κ) values. Interpretation of κ and ICC was based on 
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a classification established by Landis and Koch: poor 0.0, slight 0.0 - 0.20, fair 0.21 - 0.40, moderate 
0.41 - 0.60, good 0.61 - 0.80 and, almost-perfect 0.81 - 1.00 reproducibility (14). 
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RESULTS 
Patient characteristics and 68Ga-PSMA-11 PET/MRI detection rate 
 In this study, we analyzed 66 patients with BR and low PSA levels ≤ 0.5 ng/ml 
after primary radical prostatectomy. Patient characteristics are summarized in Table 1. 
Information of 68Ga-PSMA-11 PET/MRI detection patterns for all patients is given in Table 2. The overall 
detection rate was 54.5% including patients with prior or ongoing ADT. Subgroup analysis showed a 
detection rate of 38.5% in patients with very low PSA (0 < 0.2 ng/ml) and of 65.0% in patients with low 
PSA (0.2 - 0.5 ng/ml) levels. Excluding patients with prior or ongoing ADT slightly reduced the overall 
detection rate to 51.6%, as well as the detection rate in the very low PSA 33.3% and low PSA 63.2% 
subgroup (Figure 1). 
 Localization of suspicious lesions is shown in Figure 2. Overall, suspicious lesions 
were found in the prostatic bed (local recurrence) 15.1% (n = 10), in lymph nodes 34.8% (n = 23) and 
in bones 7.6% (n = 5). In 20 of 23 positive lymph nodes, the maximum short axis was < 8 mm, in 2 
cases 8 mm and in one case 1 cm. In the very low PSA subgroup, suspicious local recurrence was 
found in 15.3% (n = 4), lymph node metastasis in 19.2% (n = 5), and bone metastasis in 7.6% (n = 2) 
of the cohort (n = 26). In the low PSA subgroup local recurrence was detected in 15% (n = 6), lymph 
node metastasis in 45% (n = 18) and bone metastasis in 7.5% (n = 3) of the patients. A second analysis 
was performed with exclusion of all previously reported patients (n = 20) (8). In the second analysis, 
the overall detection rate was 51.1% as well as 35.3% and 60% in the very low and low PSA subgroup, 
respectively. In addition, we summarized the published literature regarding the detection rate of PSMA-
positive lesions in patients with low PSA values ≤ 1.0 ng/ml (Table 3). 
 
Localization of 68Ga-PSMA-11 PET/MRI positive lesions within a standard salvage radiotherapy 
volume 
 A re-analysis of all patients with positive findings on 68Ga-PSMA-11 PET/MRI 
discovered that in 26 of 36 patients (72.2%) with positive lesions at least one lesion would not have 
been covered by the standard RT-volume. In all 8 patients with previous RT PSMA-positive findings 
were found outside a standard RT-volume. In 18 of 28 patients without previous RT PSMA-positive 
lesions outside a standard RT-volume were detected. Overall, 68Ga-PSMA-11 PET/MRI detected 
PSMA-positive lesions outside a standard RT-volume in 26 of 66 patients (39.4%). An example of an 
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unexpected bone metastasis that would have changed RT-volume is given in Figure 3. In 4 patients, 
the PSMA-positive finding would have led to an additional boost to the focal finding, an example is given 
in Figure 4. Only in 11 patients (16.6%) with PSMA-positive findings neither RT-volume nor dosing 
would have been changed by 68Ga-PSMA-11 PET/MRI findings. 
 
Overall interreader agreement 
 Generally, the interreader agreement for all 3 readers was almost perfect (kappa 
0.855, CI 0.782-0.907). An almost perfect agreement was also detected for lymph node metastases 
(0.914, CI 0.870-0.94), for local recurrence (0.903, CI 0.855-0.938) and for bone metastases (0.851, CI 
0.776-0.904). 
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DISCUSSION 
In this study, we confirmed the previously reported promising detection rate of 68Ga-PSMA-11 
PET/MRI even in patients with PSA values ≤ 0.5 ng/ml. An overall detection rate of 65% was observed 
in patients with PSA values between 0.2 and 0.5 ng/ml. Even at low PSA values ≤ 0.5 ng/ml only 12.1% 
of all patients had PSMA-positive recurrent disease limited to the prostatic bed and extrapelvic disease 
was detected in 13.6% of the cohort. Overall, 68Ga-PSMA-11 PET/MRI would have changed the 
standard sRT volume in 39.4% of all patients. 
Given the improved opportunity of cure performing sRT in patients with PSA values below 0.5 
ng/ml, a precise re-staging for patients with BR after radical prostatectomy is of outmost interest. Ceci 
et al. published the hitherto largest cohort of 138 prospective patients with PSA values between 0.2 and 
0.5 ng/ml and found a detection rate of 37.9% using 68Ga-PSMA-11 PET/CT (15). In the same PSA 
range, Rauscher et al. presented a detection rate of 55% in 134 retrospectively analyzed patients (16). 
Farolfi et al. reported an overall detection rate of 34.4% in 119 patients (17). In addition, Afshar-Oromieh 
et al. described a detection rate of 46% in 108 patients (18). However, their cohort included not only 
patients following primary radical prostatectomy, but also following primary radiation therapy, which 
might influence the detection rate. Others reported only small cohorts including 10 to 24 patients and 
found detection rates between 36 and 57.9% (19-22). In our 68Ga-PSMA-11 PET/MRI cohort, we 
observed a considerably higher detection rate of 65% in patients presenting with PSA values between 
0.2 and 0.5 ng/ml at scan. Published data on the detection rate in patients with even lower PSA values 
< 0.2 ng/ml is scarce and includes only small patient cohorts (18,19,22,23). Reported detection rates 
for this very low PSA cohort range between 33 and 47.1%. We observed a detection rate of 38.5% for 
patients with very low PSA values < 0.2 ng/ml. 
In our cohort, only 8 of 66 patients (12.1%) were found to have PSMA-positive lesions limited 
to the prostatic bed. The most common site for PSMA-positive recurrence were lymph nodes. However, 
only 13% of the PSMA-positive lymph nodes were larger than 8 mm. This is even slightly lower, 
compared to the published data by Giesel et al. showing that only around 36% of the lymph nodes 
detected on 68Ga-PSMA-11 PET/CT are pathologically enlarged (10). 
Besides PSA levels, other factors influencing the detection rate of 68Ga-PSMA-11 PET imaging 
are currently under investigation. First preclinical data suggest that ADT might increase PSMA 
expression in vitro and in vivo (24-26). A case study by Hope et al. showed a 7-fold increase of PSMA 
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uptake in a patient treated for 4 weeks with ADT (27). Rauscher et al. published a first investigation 
trying to define predictors for 68Ga-PSMA-11 PET/CT positivity in a retrospective cohort of 272 patients 
following radical prostatectomy (16). In a multivariate analysis they found that the PSA value at scan 
(OR: 4.20, 95% CI 1.15–15.37) and concurrent ADT (OR: 9.25, 95% CI 1.17–73.31) are significant 
independent predictors of 68Ga-PSMA-11 PET/CT positivity. On the other hand, a first prospective trial 
in 8 patients with serial 68Ga-PSMA-11 PET scans 9, 18 and 28 days after the start of ADT did not 
confirm the expected transient rise in 68Ga-PSMA-11 uptake (28) and a retrospective analysis of 10 
patients found that continuous long-term ADT between 42 and 369 days significantly reduced the 
visibility of castration-sensitive prostate cancer in 68Ga-PSMA-11 PET/CT (29). In our cohort, only 4 
patients had ongoing or prior ADT at the time of scan. In all these patients, PSMA positive lymph nodes 
were found, even at very low PSA values. Though, additional investigations need to further elucidate 
the impact of ADT on the uptake of 68Ga-PSMA-11 in different settings and tumor stages. Apart from 
the above mentioned factors also PSMA-tracer kinetics seem to impact the detection rate in patients 
with BR. Newly introduced 18F-PSMA-1007 shows only minimal activity in the urinary tract possibly 
improving the detection of local recurrence or loco-regional lymph nodes (30,31). However, studies 
directly comparing the detection rate of 68Ga-PSMA-11 and 18F-PSMA-1007 have not yet been 
performed. 
In addition, a rapidly increasing body of literature investigates the alteration of RT management 
based on 68Ga-PSMA-11 imaging. However, these are commonly rather small cohorts with a wide PSA 
range. A change in RT planning or management was described in 50 to 77% of all patients using 68Ga-
PSMA-11 PET/CT (32-34). In addition, it has been shown that 68Ga-PSMA-11 PET/CT based RT leads 
to a significant PSA response in patients with biochemical recurrence (5,6). In our cohort 68Ga-PSMA-
11 PET/MRI positive lesions outside a standard RT-volume were found in more than 70% of all patients 
with PSMA-positive lesions. However, the impact of targeted RT on cancer-specific survival or time to 
cancer recurrence is still unknown. Future investigations will need to reveal whether targeted treatment 
of oligo-metastatic disease based on 68Ga-PSMA-11 PET/MRI improves cancer-specific survival. 
A limitation of our study is its retrospective nature leading to an inherent selection bias. Due to 
retrospective data acquisition there is a lack of clinical information in some patients. Furthermore, the 
reported patient collective is still relatively small and lacks a comparison to histopathology of PSMA-
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positive lesions. However, it is the largest cohort investigating the impact of 68Ga-PSMA-11 PET/MRI 
in patients with very low PSA values and recurrent prostate cancer  
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CONCLUSION 
Our data confirms that 68Ga-PSMA-11 PET/MRI has a high detection rate for recurrent prostate 
cancer even at low PSA levels ≤ 0.5 ng/ml. In addition, we show that 68Ga-PSMA-11 PET/MRI detected 
PSMA-positive lesions outside a standard salvage radiotherapy volume in nearly 40% of all patients. 
 
KEY POINTS 
 
Question: How many PSMA-positive lesions were located outside a standard salvage radiotherapy field 
within the presented cohort? 
 
Pertinent findings: This retrospective analysis focusing on the detection rate of 68Ga-PSMA-11 PET/MRI 
in patients with recurrent prostate cancer and low PSA values ≤ 0.5 ng/ml revealed an overall detection 
rate of 54.5%. Moreover, in 65% of all patients with a PSA between 0.2 - 0.5 ng/ml PSMA-positive 
lesions were detected, making this imaging modality a promising tool for re-staging of prostate cancer. 
 
Implications for patient care: The results of this study encourage to further investigate the value of 68Ga-
PSMA-11 PET/MRI in patients with recurrent prostate cancer and low PSA values. 
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Figure 1: 68Ga-PSMA-11 PET/MRI detection rate stratified by different PSA levels at time of scan. A 
separate analysis has been performed including patients with ongoing or prior androgen deprivation 
therapy (ADT). Data is shown as percentage of events. 
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Figure 2: Number of 68Ga-PSMA-11 PET/MRI positive events stratified by localization and PSA levels 
at time of scan. Androgen deprivation therapy (ADT) prior to the scan increased the detection of positive 
lymph nodes metastases. Data is shown as total number of events 
  
 16 
 
 
Figure 3: 57-year old patient referred to 68Ga-PSMA-11 PET/MRI after prostatectomy for a pT1c, pN0, 
cM0, Gleason 7 tumor with a PSA of 0.5 ng/ml. a) There is no focal uptake clearly delineated on the 
coronal MIP. b) On axial PET a focal uptake in the processus spinosus of the 12th thoracic vertebra was 
seen (SUVmax 5.6), c) corresponding to a minimal contrast enhancing focus on axial post contrast T1-
fat sat imaging. d) Correlation is confirmed on the fused images (arrow). 
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Figure 4: 73-year old patient referred to 68Ga-PSMA-11 PET/MRI after prostatectomy for a pT3a, pN0, 
cM0 Gleason 7 and a rise in PSA to 0.41 ng/ml 3.5 years after prostatectomy. a) Coronal MIP showed 
solitary intense focal PSMA-uptake in a left internal iliac area (arrow). b) Focal uptake was confirmed 
on axial PET (SUVmax 23), c) corresponding to a non-enlarged lymph node in the left iliac internal region 
on axial T1-weighted sequence and d) the fused PET/MRI (arrow). Based on the assessment of our 
radiation oncologist, this finding would change the radiation plan. 
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Table 1: Clinical patient characteristics 
Characteristics N = 66 
Age at scan (y) 65     (10) 
PSA (ng/ml) 
     PSA at initial treatment 
     PSA at scan time 
 
8.9    (9.4) 
0.2    (0.2) 
Primary tumor stage (n) 
     ≤ pT2c 
     ≥ pT3a 
     n/a 
 
27    (40.9%) 
34    (51.5%) 
5      (7.6%) 
Primary lymph node stage (n) 
     pN0 
     pN1 
     n/a 
 
47    (71.2%) 
11    (16.7%) 
8      (12.1%) 
Gleason score (n) 
     7 
     8 
     9 
     n/a 
 
36    (54.5%) 
8      (12.1%) 
16    (24.2%) 
6      (9.2%) 
Resection status (n) 
     R0 
     R1 
     n/a 
 
23    (34.8%) 
28    (42.4%) 
15    (22.7%) 
ADT 
     prior to scan (n) 
     ongoing at the time of scan (n) 
 
2      (3.0%) 
2      (3.0%) 
RT 
     RT prior to scan (n) 
 
13    (19.7%) 
 
Data presented as median (interquartile range) or number (percent) 
ADT: Androgen deprivation therapy, RT: Radiotherapy, n/a: not available 
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Table 2: Overall detection rate in patients with PSA values ≤ 0.5 ng/ml 
Nr PSA (ng/ml) ADT RT LR SUVmax LN SUVmax 
LN 
Size (mm) 
LN 
location BM SUVmax 
Dosage 
(MBq) 
1 0.03 previous - -  + 6.1 3 1 -  138 
2 0.05 - - -  + 3.9 4 1 -  107 
3 0.05 - - -  -    -  120 
4 0.06 - - -  -    -  115 
5 0.07 - - -  -    -  153 
6 0.08 ongoing - -  + 17.1 4 2 -  90 
7 0.08 - - -  -    -  114 
8 0.08 - - -  -    -  115 
9 0.09 - - -  -    -  146 
10 0.1 - aRT -  -    -  154 
11 0.11 - - -  -    -  143 
12 0.12 - - -  -    -  120 
13 0.13 - - -  -    -  150 
14 0.13 - - -  -    -  110 
15 0.14 - sRT -  -    + 4.1 113 
16 0.14 - - + 4 -    -  120 
17 0.15 - sRT -  + 15 8 1 -  126 
18 0.15 - - + 4.5 -    -  140 
19 0.16 - - + 5.3 -    + 4.65 126 
20 0.16 - - + 10.8 -    -  128 
21 0.16 - - -  -    -  107 
22 0.17 - - -  -    -  102 
23 0.17 - - -  -    -  152 
24 0.17 - - -  -    -  113 
25 0.18 - sRT -  + 12.4 8 1 -  104 
26 0.19 - - -  -    -  134 
27 0.2 ongoing - -  + 4.1 10 1,2 -  143 
28 0.2 - - -  + 5 5 2 -  143 
29 0.2 - - -  -    -  126 
30 0.2 - sRT -  -    -  120 
31 0.21 - sRT -  + 18 4 1 -  121 
32 0.22 - - -  + 6.4 3 1 -  101 
33 0.22 - - -  -    -  122 
34 0.25 - - -  + 25.6 7 1 -  144 
35 0.26 - - -  -    + 3.9 147 
36 0.27 - sRT -  + 3.7 4 1 -  145 
37 0.29 - - -  -    -  140 
38 0.29 - - -  + 2.7 3 1 -  131 
39 0.3 - - -  -    -  139 
40 0.3 - - + 9.1 -    -  141 
41 0.31 previous sRT -  + 4.9 4 1 -  107 
42 0.31 - - + 5 -    -  126 
43 0.31 - - -  -    -  120 
44 0.31 - - -  -    -  122 
45 0.33 - - -  -    + 5 137 
46 0.33 - - -  -    -  136 
47 0.34 - sRT -  + 7.1 6 1 -  108 
48 0.34 - - -  + 6 3 1 -  152 
49 0.34 - - -  -    -  137 
50 0.36 - sRT -  -    -  128 
51 0.37 - - -  -    -  108 
52 0.37 - - -  -    -  122 
53 0.37 - - -  -    -  148 
54 0.38 - - -  + 12.6 5 1 -  147 
55 0.4 - - + 13.9 -    -  113 
56 0.4 - - + 4.9 + 4.1 5 1 -  150 
57 0.4 - - -  + 20 5 1 -  132 
58 0.41 - - -  + 23.7 7 1 -  135 
59 0.45 - - -  -    -  142 
60 0.45 - aRT + 13.7 -    -  137 
61 0.45 - - -  + 9.4 3 1 -  154 
62 0.46 - - -  + 17.1 6 1, 2 -  122 
63 0.49 - sRT + 4.4 -    -  143 
64 0.49 - - -  + 5.5 6 1 -  162 
65 0.5 - - -  + 11.7 5 1 -  140 
66 0.5 - sRT -  -    + 5.6 151 
 
PSA: Prostate Specific Antigen, LR: Local recurrence, LN: Lymph node metastasis, LN: Lymph node, BM: Bone metastasis, SUVmax: 
Maximum Standardized Uptake Value, s/aRT: salvage/adjuvant Radiotherapy, LN location: 1=pelvic, 2=paraaortal, 
3=mediastinal/supraclavicular, 4=axillary 
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Table 3: Reported detection rates in patients with very low PSA values at scan 
Author Year Imaging modality n 
PSA 
range 
(ng/ml) 
PSMA 
positive 
lesions 
(%) 
a) PSA at scan  ≤0.5 ng/ml 
Afshar-Oromieh et al. (18) 2017 PET/CT 69 
108 
0 - 0.2 
0.21 - 0.5 
46 
46 
Afshar-Oromieh et al. (19) 2015 PET/CT 17 
10 
0 - 0.2 
0.21 - 0.5 
47.1 
50 
Caroli et al. (35) 2018 PET/CT n/a 0 - 0.2 27.3 
Ceci et al. (15) 2019 PET/CT 138 0.2 - 0.5 37.9 
Eiber et al. (20) 2015 PET/CT 19 0.2 - 0.5 57.9 
Farolfi et al. (17) 2018 PET/CT 119 0.2 - 0.5 34.4 
Hamed etl al. (21) 2018 PET/CT 24 0 - <0.5  54.2 
Kabaskal et al. (23) 2016 PET/CT 12 0 - <0.2 33 
Kranzbühler et al. (8) 2017 PET/MRI 9 
11 
0 - 0.2 
0.2 - 0.5 
44.4 
72.7 
Morigi et al. (36) 2015 PET/CT 16 0 - 0.5 50 
Rauscher et al. 2018 PET/CT 134 0.2 – 0.5 55 
Schmidt-Hegemann et al. (22) 2017 PET/CT n/a 
n/a 
0 - 0.2 
0.21 - 0.5 
33.3 
41.2 
Van Leeuwen et al. (37) 2016 PET/CT 13 
22 
17 
11 
0.05 - 0.09 
0.1 - 0.19 
0.2 – 0.29 
0.3 – 0.49 
8 
23 
58 
36 
b) PSA at scan ≤1.0 ng/ml 
Calais et al. (38) 2017 PET/CT 270 0 - <1 49 
Caroli et al. (35) 2018 PET/CT n/a 0.2 - 1 47.1 
Ceci et al. (15) 2019 PET/CT 92 0.51 - 1 53.6 
Eiber et al. (20)  2015 PET/CT 33 0.5 - <1 72.7 
Hamed et al. (21) 2018 PET/CT 35 0.5 - <1 71.4 
Rauscher et al. 2018 PET/CT 138 >0.5 - 1 74 
Van Leeuwen et al. (37) 2016 PET/CT 7 0.5 – 0.99 57 
Verburg et al. (39) 2016 PET/CT 27 0 - <1 44 
 
n/a: not available, PSA: prostate-specific antigen 
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